EMA Authorised: Vevizye (ciclosporin) — Laboratoires Théa

View source ↗

Summary

The EMA has authorised Vevizye, an ophthalmic ciclosporin product from Laboratoires Théa, for keratoconjunctivitis sicca (dry eye disease).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Keratoconjunctivitis Sicca

Drugs mentioned

• Vevizye (ciclosporin)

Snippet

Status: Authorised. Therapeutic area: Keratoconjunctivitis Sicca. MAH: Laboratoires Théa. Decision date: 23/04/2025